The Economic Times
English EditionEnglish Editionहिन्दी
| 27 November, 2020, 08:37 PM IST | E-Paper
Search
+

    Biotech

    Zydus Cadila to apply for Phase-3 trials in December, hopes to launch vaccine by March

    The Ahmedabad-based drug maker will submit the results of its phase-2 trials next week, which "will ascertain the safety, dose and efficacy of the potential vaccine", said the person who requested not to be identified.

    There are over 200 COVID-19 vaccines currently in development, here's what you need to know

    A breakdown of everything we know about the most likely vaccine candidates, the countries that have first access and who's manufacturing for whom and where.

    Making functional human tissues is just a start for Pandorum Tech

    ​​Pandorum is backed by the Indian Angel Network, Flipkart cofounder Binny Bansal, Hero Group promoter Sunil Munjal and the Biotechnology Industry Research Assistance Council.

    When the pandemic hit, India's healthcare industry was quick to adapt to the need of the hour

    Indian diagnostic companies had experience in developing test assays for dengue, HIV, TB and H1N1, but with Covid-19 the delay in getting hold of the genetic code of SARS-Cov2 meant the Indian government, in the initial months of the pandemic, had to wait on imported RT-PCR kits that were expensive with worldwide shortage. In March, the Indian Council of Medical Research placed an order of one million probes from Germany.

    Oxford vaccine: Kiran Mazumdar-Shaw seeks quick regulatory processing after UK nod

    She cited reports according to which the UK's medicines and healthcare products regulatory agency (MHRA) is likely to grant EUA by mid December. A couple of weeks later, she said, the drugs controller general of India (DCGI) could allow it for emergency use in India.

    Indian vaccine makers - Serum and Gennova - set to host over 20 foreign diplomats this week

    The move comes as the Indian government thinks that it has sufficient doses of vaccine for its population and can also supply to other nations that might be left out in the Covid-19 vaccine race as countries in Europe and US secure their own doses, said an official.

    First animal study in India on coronavirus moves to its final stage, says AYUSH Ministry

    The clinical studies are being pursued through another collaboration of the Ministry of AYUSH, the partner in this one being the Council for Scientific and Industrial Research (CSIR).

    Biological E gets DGCA nod to begin the next phase of trials for its COVID-19 vaccine

    This vaccine candidate includes an antigen that was in-licensed from BCM Ventures, which is an integrated commercialisation team of Baylor College of Medicine in Houston, and an advanced adjuvant from the US-based vaccine focused pharmaceutical firm Dynavax Technologies Corporation.

    Bharat Biotech begins Phase-III trials for COVID-19 vaccine, Covaxin, with 26,000 volunteers

    "This is India's first phase-III efficacy study for a Covid-19 vaccine, and the largest phase-III efficacy trial ever conducted in India," said Bharat Biotech in a statement on Monday, adding that the trial was registered at ICMR and approved by the Drugs Controller General of India.

    Serum says made 40 mn doses of AstraZeneca's COVID vaccine, to make Novavax shot soon

    Serum said it has enrolled 1,600 participants in India for late-stage trials of AstraZeneca's candidate, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine.

    Gennova Biopharma to start mRNA vaccine trials by the year's end; results likely in March '21

    Gennova Biopharma to start mRNA vaccine trials by the year's end; results likely in March '21

    The trial results are likely to come in by March 2021, Sanjay Singh, CEO of Pune-based Gennova, told ET. There is a possibility that India may pitch the locally made vaccine to other countries.

    Pfizer starts talks with Covax facility for equitable distribution of COVID-19 vaccine

    Pfizer starts talks with Covax facility for equitable distribution of COVID-19 vaccine

    The company is in discussions with the Gavi vaccine alliance to potentially provide doses to the Covax facility, a Pfizer spokesperson told ET, adding: "It is our intention to achieve equitable global distribution of vaccine supply in alignment with identified priority populations."

    The understated husband-and-wife 'dream team' behind Pfizer's coronavirus vaccine

    The understated husband-and-wife 'dream team' behind Pfizer's coronavirus vaccine

    Pfizer and BioNTech are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek U.S. emergency use authorization later this month.

    Pfizer's coronavirus vaccine isn't expected to reach India anytime soon; US, UK first in line

    Pfizer's coronavirus vaccine isn't expected to reach India anytime soon; US, UK first in line

    The extremely stringent temperature requirement for mRNA vaccines, which is what the Pfizer vaccine candidate is based on, will also make it difficult to be used in India as part of a national immunisation strategy, experts said.

    Biocon Biologics to receive $150 million from Goldman Sachs against convertible debentures

    Biocon Biologics to receive $150 million from Goldman Sachs against convertible debentures

    “The Board of its (Biocon’s) subsidiary Biocon Biologics has approved a Rs 1,125 Crore ($150 million) capital injection from Goldman Sachs. As per the terms of the proposed agreement, Goldman Sachs will be issued optionally convertible debentures at a post money equity valuation of $ 3.94 Billion,” said Biocon in a press release.

    Biocon ranked among top five biotech employers globally

    Biocon ranked among top five biotech employers globally

    Ranked at number five among global pharma and biotech companies in 2020, the Bengaluru-headquartered biopharmaceuticals company said it has moved up from number seven in 2018 and number six in 2019.

    Load More...
    The Economic Times
    BACK TO TOP